# Hamburg Edoxaban for Anticoagulation in COVID-19 Study

> **NCT04542408** · PHASE3 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 140 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Anticoagulation Agents (Edoxaban and/or high dose LMWH)
- **DRUG:** Low dose Low molecular weight heparin or Placebo

## Key facts

- **NCT ID:** NCT04542408
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2022-09-06
- **Final completion:** 2023-01-15
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2023-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542408, "Hamburg Edoxaban for Anticoagulation in COVID-19 Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04542408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*